Alan Abboud

Mr. Alan Abboud

Stony Brook University Hospital, Stony Brook, New York, USA
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2024 in Journal of Brown Hospital Medicine
Verified
Journal Article
Open access
PDF file
AAAlan Abboud
Alan Abboud
KUKazi Ullah
Kazi Ullah
LKLeslie Klyachman
Leslie Klyachman
EHEmily B. Huang
Emily B. Huang
RCRasan Cherala
Rasan Cherala
Turmeric and its active compound, curcumin, has gained popularity as an herbal supplement due to its anti-inflammatory properties. However, the lack of standardized regulation for herbal supplements raises concerns about potential side effects and toxicity. This case report presents a 53-year-old woman with Behçet disease who developed biopsy-proven drug-induced liver injury (DILI) after initiating a turmeric supplement, with resolution of laboratory abnormalities after a positive supplement de-challenge. This case highlights the importance of noting herbal supplementation during medication reconciliation and underscores the need for rigorous regulatory oversight to ensure the safety of such products.

27 October 2025 in Naunyn-Schmiedeberg's Archives of Pharmacology
Verified
Journal Article
Closed access
PDF file
FAFeyzullah Aksan
Feyzullah Aksan
AAAlan Abboud
Alan Abboud
Lokman H. TanriverdiLokman H. Tanriverdi
Lokman H. Tanriverdi
OAOlga C. Aroniadis
Olga C. Aroniadis
FMFarah Monzur
Farah Monzur

9 August 2025 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
AAAlan Abboud
Alan Abboud
ATAmin Tajerian
Amin Tajerian
SCSharon Charles
Sharon Charles
MCMichael Clores
Michael Clores
MGMarc Goldschmidt
Marc Goldschmidt
Andreas KalogeropoulosAndreas Kalogeropoulos
Andreas Kalogeropoulos

22 September 2022 in Journal of Personalized Medicine
Verified
Journal Article
Open access
PDF file
BMBrandon Muncan
Brandon Muncan
AAAlan Abboud
Alan Abboud
APAikaterini Papamanoli
Aikaterini Papamanoli
MJMark Jacobs
Mark Jacobs
AMAllison J. McLarty
Allison J. McLarty
Andreas KalogeropoulosAndreas Kalogeropoulos
Andreas Kalogeropoulos
Background: Disparities in treatment and outcomes of infective endocarditis (IE) between people who use drugs (PWUD) and non-PWUD have been reported, but long-term data on cardiovascular and cerebrovascular outcomes are limited. We aim to compare 5-year rates of mortality, cardiovascular and cerebrovascular events after IE between PWUD and non-PWUD. Methods: Using data from the TriNetX Research Network, we examined 5-year cumulative incidence of mortality, myocardial infarction, heart failure, atrial fibrillation/flutter, ventricular tachyarrhythmias, ischemic stroke, and intracranial hemorrhage in 7132 PWUD and 7132 propensity score-matched non-PWUD patients after a first episode of IE. We used the Kaplan–Meier estimate for incidence and Cox proportional hazards models to estimate relative risk. Results: Matched PWUD were 41 ± 12 years old; 52.2% men; 70.4% White, 19.8% Black, and 8.0% Hispanic. PWUD had higher mortality vs. non-PWUD after 1 year (1–3 year: 9.2% vs. 7.5%, p = 0.032; and 3–5-year: 7.3% vs. 5.1%, p = 0.020), which was largely driven by higher mortality among female patients. PWUD also had higher rates of myocardial infarction (10.0% vs. 7.0%, p < 0.001), heart failure (19.3% vs. 15.2%, p = 0.002), ischemic stroke (8.3% vs. 6.3%, p = 0.001), and intracranial hemorrhage (4.1% vs. 2.8%, p = 0.009) compared to non-PWUD. Among surgically treated PWUD, interventions on the tricuspid valve were more common; however, rates of all outcomes were comparable to non-PWUD. Conclusions: PWUD had higher 5-year incidence of cardiovascular and cerebrovascular events after IE compared to non-PWUD patients. Prospective investigation into the causes of these disparities and potential harm reduction efforts are needed.